Concepts (222)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Oligonucleotides, Antisense | 17 | 2024 | 132 | 6.910 |
Why?
|
| Oligonucleotides | 19 | 2024 | 205 | 4.580 |
Why?
|
| RNA, Small Interfering | 14 | 2024 | 850 | 3.170 |
Why?
|
| Gene Silencing | 11 | 2024 | 376 | 2.360 |
Why?
|
| Gene Editing | 9 | 2024 | 280 | 2.190 |
Why?
|
| RNA | 10 | 2024 | 400 | 1.630 |
Why?
|
| Nucleic Acids | 2 | 2022 | 50 | 1.380 |
Why?
|
| RNA Interference | 8 | 2024 | 588 | 1.170 |
Why?
|
| RNA, Double-Stranded | 6 | 2020 | 107 | 1.080 |
Why?
|
| CRISPR-Cas Systems | 5 | 2024 | 316 | 1.080 |
Why?
|
| Fibroblasts | 4 | 2022 | 366 | 0.930 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2024 | 177 | 0.930 |
Why?
|
| Friedreich Ataxia | 2 | 2022 | 4 | 0.890 |
Why?
|
| DNA | 10 | 2024 | 784 | 0.870 |
Why?
|
| Brain Neoplasms | 2 | 2024 | 305 | 0.850 |
Why?
|
| Glioblastoma | 1 | 2024 | 150 | 0.820 |
Why?
|
| Splints | 1 | 2021 | 5 | 0.790 |
Why?
|
| Arabinonucleotides | 3 | 2010 | 4 | 0.770 |
Why?
|
| RNA, Messenger | 5 | 2022 | 1461 | 0.760 |
Why?
|
| Gene Expression Regulation | 6 | 2022 | 1535 | 0.750 |
Why?
|
| Endothelial Cells | 1 | 2022 | 175 | 0.740 |
Why?
|
| Phenotype | 1 | 2024 | 1151 | 0.720 |
Why?
|
| Genetic Therapy | 4 | 2021 | 704 | 0.720 |
Why?
|
| Mice | 15 | 2024 | 10220 | 0.710 |
Why?
|
| Proprotein Convertase 9 | 1 | 2020 | 12 | 0.690 |
Why?
|
| Acetylgalactosamine | 2 | 2024 | 10 | 0.680 |
Why?
|
| Animals | 23 | 2024 | 19531 | 0.670 |
Why?
|
| Peptide Nucleic Acids | 2 | 2018 | 17 | 0.670 |
Why?
|
| Lung | 3 | 2023 | 818 | 0.660 |
Why?
|
| RNA, Long Noncoding | 2 | 2018 | 151 | 0.640 |
Why?
|
| Drug Delivery Systems | 4 | 2022 | 302 | 0.640 |
Why?
|
| Triazoles | 2 | 2018 | 55 | 0.600 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 94 | 0.590 |
Why?
|
| RNAi Therapeutics | 1 | 2017 | 12 | 0.570 |
Why?
|
| Monosaccharides | 2 | 2007 | 7 | 0.550 |
Why?
|
| Uridine | 2 | 2007 | 15 | 0.550 |
Why?
|
| Humans | 34 | 2024 | 59008 | 0.520 |
Why?
|
| Cells, Cultured | 5 | 2022 | 2090 | 0.470 |
Why?
|
| Antiviral Agents | 2 | 2023 | 314 | 0.460 |
Why?
|
| Phosphorothioate Oligonucleotides | 2 | 2024 | 10 | 0.440 |
Why?
|
| Organophosphorus Compounds | 3 | 2023 | 32 | 0.440 |
Why?
|
| Central Nervous System | 2 | 2024 | 190 | 0.410 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 823 | 0.400 |
Why?
|
| Iron-Binding Proteins | 2 | 2022 | 10 | 0.360 |
Why?
|
| Thermodynamics | 2 | 2010 | 194 | 0.350 |
Why?
|
| RNA, Antisense | 1 | 2010 | 48 | 0.350 |
Why?
|
| Liver | 4 | 2024 | 780 | 0.330 |
Why?
|
| Transcriptional Activation | 1 | 2010 | 188 | 0.330 |
Why?
|
| Organoselenium Compounds | 1 | 2008 | 4 | 0.310 |
Why?
|
| Oligoribonucleotides | 1 | 2008 | 14 | 0.310 |
Why?
|
| Aptamers, Nucleotide | 2 | 2021 | 18 | 0.310 |
Why?
|
| Cell Line, Tumor | 4 | 2024 | 1362 | 0.300 |
Why?
|
| Genome, Human | 2 | 2021 | 217 | 0.300 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 656 | 0.280 |
Why?
|
| Nanoparticles | 3 | 2021 | 493 | 0.260 |
Why?
|
| Base Sequence | 7 | 2022 | 1309 | 0.250 |
Why?
|
| Models, Molecular | 4 | 2021 | 1113 | 0.240 |
Why?
|
| Trinucleotide Repeat Expansion | 3 | 2023 | 33 | 0.240 |
Why?
|
| Molecular Conformation | 3 | 2017 | 132 | 0.240 |
Why?
|
| Ribonuclease H | 2 | 2018 | 18 | 0.230 |
Why?
|
| C9orf72 Protein | 2 | 2022 | 98 | 0.230 |
Why?
|
| DNA, Single-Stranded | 2 | 2022 | 100 | 0.230 |
Why?
|
| RNA Splicing | 2 | 2022 | 161 | 0.220 |
Why?
|
| Mice, Nude | 1 | 2024 | 257 | 0.220 |
Why?
|
| Adenine | 1 | 2024 | 45 | 0.220 |
Why?
|
| Technology | 1 | 2023 | 50 | 0.220 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2023 | 15 | 0.220 |
Why?
|
| Endonucleases | 1 | 2023 | 81 | 0.220 |
Why?
|
| Drug Design | 2 | 2017 | 143 | 0.210 |
Why?
|
| Fragile X Syndrome | 1 | 2023 | 28 | 0.210 |
Why?
|
| DNA Repair | 2 | 2021 | 225 | 0.210 |
Why?
|
| Trachea | 1 | 2022 | 92 | 0.200 |
Why?
|
| Cytidine Deaminase | 1 | 2022 | 81 | 0.200 |
Why?
|
| Motor Activity | 1 | 2024 | 342 | 0.190 |
Why?
|
| Trypsin | 1 | 2021 | 40 | 0.190 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 191 | 0.190 |
Why?
|
| Endoribonucleases | 1 | 2021 | 52 | 0.190 |
Why?
|
| Cells | 1 | 2021 | 30 | 0.180 |
Why?
|
| Chromatids | 1 | 2020 | 13 | 0.180 |
Why?
|
| Chromosome Segregation | 1 | 2020 | 39 | 0.180 |
Why?
|
| Frontotemporal Dementia | 1 | 2022 | 126 | 0.180 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2021 | 111 | 0.180 |
Why?
|
| Germany | 1 | 2019 | 51 | 0.170 |
Why?
|
| Circular Dichroism | 3 | 2010 | 104 | 0.170 |
Why?
|
| Disease Models, Animal | 2 | 2023 | 2051 | 0.160 |
Why?
|
| Solid-Phase Synthesis Techniques | 1 | 2018 | 3 | 0.160 |
Why?
|
| Zebrafish | 1 | 2021 | 323 | 0.160 |
Why?
|
| Water | 2 | 2010 | 294 | 0.160 |
Why?
|
| Transcription Factor 4 | 1 | 2018 | 2 | 0.150 |
Why?
|
| Fuchs' Endothelial Dystrophy | 1 | 2018 | 3 | 0.150 |
Why?
|
| Macromolecular Substances | 1 | 2018 | 159 | 0.150 |
Why?
|
| Chromatin | 2 | 2020 | 591 | 0.150 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2022 | 474 | 0.140 |
Why?
|
| Hepatocytes | 1 | 2018 | 187 | 0.140 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2018 | 166 | 0.140 |
Why?
|
| Nucleosides | 2 | 2007 | 11 | 0.140 |
Why?
|
| DNA-Binding Proteins | 1 | 2022 | 1128 | 0.140 |
Why?
|
| Escherichia coli | 1 | 2021 | 676 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 117 | 0.130 |
Why?
|
| Nucleic Acid Conformation | 3 | 2020 | 231 | 0.130 |
Why?
|
| MCF-7 Cells | 1 | 2016 | 64 | 0.130 |
Why?
|
| ADAM Proteins | 1 | 2016 | 34 | 0.130 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 275 | 0.130 |
Why?
|
| Cell Membrane | 1 | 2018 | 489 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 712 | 0.130 |
Why?
|
| Caenorhabditis elegans | 1 | 2021 | 613 | 0.120 |
Why?
|
| Molecular Imprinting | 1 | 2014 | 4 | 0.120 |
Why?
|
| Binding Sites | 1 | 2017 | 872 | 0.120 |
Why?
|
| Alleles | 2 | 2018 | 424 | 0.120 |
Why?
|
| RNA Polymerase II | 2 | 2014 | 70 | 0.120 |
Why?
|
| Hepacivirus | 1 | 2015 | 140 | 0.110 |
Why?
|
| Mutation | 1 | 2021 | 2420 | 0.110 |
Why?
|
| Nucleic Acid Denaturation | 2 | 2010 | 7 | 0.110 |
Why?
|
| Models, Genetic | 1 | 2014 | 253 | 0.110 |
Why?
|
| Cations | 2 | 2011 | 63 | 0.110 |
Why?
|
| Hydrogen Bonding | 2 | 2010 | 125 | 0.110 |
Why?
|
| MicroRNAs | 2 | 2024 | 617 | 0.100 |
Why?
|
| Molecular Structure | 2 | 2011 | 374 | 0.100 |
Why?
|
| Spermine | 1 | 2011 | 2 | 0.100 |
Why?
|
| Polymers | 1 | 2014 | 315 | 0.090 |
Why?
|
| Alternative Splicing | 1 | 2011 | 121 | 0.090 |
Why?
|
| Transcription Factors | 2 | 2018 | 1453 | 0.090 |
Why?
|
| Male | 4 | 2024 | 27369 | 0.090 |
Why?
|
| Fluorine | 1 | 2010 | 9 | 0.090 |
Why?
|
| Receptors, Progesterone | 1 | 2010 | 109 | 0.080 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2010 | 110 | 0.080 |
Why?
|
| Protein Biosynthesis | 1 | 2011 | 290 | 0.080 |
Why?
|
| Crotalus | 1 | 2009 | 1 | 0.080 |
Why?
|
| 2',3'-Cyclic-Nucleotide Phosphodiesterases | 1 | 2009 | 3 | 0.080 |
Why?
|
| Alkalies | 1 | 2009 | 3 | 0.080 |
Why?
|
| Viper Venoms | 1 | 2009 | 2 | 0.080 |
Why?
|
| RNA, Untranslated | 1 | 2010 | 101 | 0.080 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 337 | 0.080 |
Why?
|
| Acids | 1 | 2009 | 14 | 0.080 |
Why?
|
| Stereoisomerism | 1 | 2009 | 68 | 0.080 |
Why?
|
| Hydrolysis | 1 | 2009 | 138 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2011 | 335 | 0.080 |
Why?
|
| Catalysis | 1 | 2009 | 152 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 435 | 0.080 |
Why?
|
| Biophysical Phenomena | 1 | 2008 | 20 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2010 | 201 | 0.080 |
Why?
|
| Biophysics | 1 | 2008 | 42 | 0.080 |
Why?
|
| Nucleotides | 1 | 2008 | 41 | 0.080 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2008 | 104 | 0.080 |
Why?
|
| Research Design | 1 | 2011 | 561 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 1 | 2011 | 422 | 0.080 |
Why?
|
| HEK293 Cells | 2 | 2021 | 566 | 0.070 |
Why?
|
| Introns | 2 | 2018 | 106 | 0.070 |
Why?
|
| Carbohydrate Conformation | 1 | 2007 | 15 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 758 | 0.070 |
Why?
|
| Glycosylation | 1 | 2006 | 134 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2006 | 290 | 0.060 |
Why?
|
| Antagomirs | 1 | 2024 | 5 | 0.060 |
Why?
|
| Apolipoproteins E | 1 | 2024 | 99 | 0.060 |
Why?
|
| Templates, Genetic | 1 | 2023 | 21 | 0.060 |
Why?
|
| Tissue Distribution | 1 | 2024 | 280 | 0.050 |
Why?
|
| APOBEC-3G Deaminase | 1 | 2022 | 21 | 0.050 |
Why?
|
| Neurons | 2 | 2021 | 854 | 0.050 |
Why?
|
| Fragile X Mental Retardation Protein | 1 | 2023 | 37 | 0.050 |
Why?
|
| Biotinylation | 1 | 2022 | 38 | 0.050 |
Why?
|
| Dipeptides | 1 | 2022 | 62 | 0.050 |
Why?
|
| Exons | 1 | 2022 | 192 | 0.050 |
Why?
|
| Catalytic Domain | 1 | 2022 | 184 | 0.050 |
Why?
|
| Biotin | 1 | 2022 | 52 | 0.050 |
Why?
|
| K562 Cells | 1 | 2021 | 58 | 0.050 |
Why?
|
| Precision Medicine | 1 | 2022 | 102 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 248 | 0.050 |
Why?
|
| Cell-Free System | 1 | 2021 | 31 | 0.050 |
Why?
|
| Peptide Chain Initiation, Translational | 1 | 2021 | 20 | 0.050 |
Why?
|
| Surface Plasmon Resonance | 1 | 2021 | 33 | 0.050 |
Why?
|
| Genes, Reporter | 1 | 2022 | 243 | 0.050 |
Why?
|
| Serum Albumin, Bovine | 1 | 2021 | 33 | 0.050 |
Why?
|
| Muramidase | 1 | 2021 | 47 | 0.050 |
Why?
|
| Ribonucleoproteins | 1 | 2022 | 112 | 0.050 |
Why?
|
| G-Quadruplexes | 1 | 2020 | 6 | 0.040 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2020 | 27 | 0.040 |
Why?
|
| Goals | 1 | 2021 | 89 | 0.040 |
Why?
|
| Cell Line | 2 | 2018 | 2011 | 0.040 |
Why?
|
| Genome | 1 | 2022 | 252 | 0.040 |
Why?
|
| Biosensing Techniques | 1 | 2021 | 114 | 0.040 |
Why?
|
| Mitosis | 1 | 2020 | 207 | 0.040 |
Why?
|
| Escherichia coli Proteins | 1 | 2021 | 251 | 0.040 |
Why?
|
| Particle Size | 1 | 2020 | 397 | 0.040 |
Why?
|
| DNA Replication | 1 | 2020 | 229 | 0.040 |
Why?
|
| Endothelium, Corneal | 1 | 2018 | 1 | 0.040 |
Why?
|
| Oligoribonucleotides, Antisense | 1 | 2018 | 2 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 1219 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2018 | 106 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2018 | 75 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2018 | 453 | 0.040 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2018 | 84 | 0.040 |
Why?
|
| Biomarkers | 1 | 2022 | 1201 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2024 | 3176 | 0.030 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2018 | 248 | 0.030 |
Why?
|
| Proteins | 1 | 2022 | 742 | 0.030 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2020 | 527 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2018 | 453 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 672 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 192 | 0.030 |
Why?
|
| Cell Membrane Permeability | 1 | 2011 | 38 | 0.020 |
Why?
|
| Ataxin-3 | 1 | 2011 | 3 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2011 | 90 | 0.020 |
Why?
|
| Transition Temperature | 1 | 2010 | 5 | 0.020 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2010 | 28 | 0.020 |
Why?
|
| Luciferases, Firefly | 1 | 2010 | 17 | 0.020 |
Why?
|
| Interferons | 1 | 2010 | 64 | 0.020 |
Why?
|
| RNA Stability | 1 | 2010 | 91 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2010 | 216 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2011 | 304 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 5058 | 0.020 |
Why?
|
| Child | 1 | 2018 | 4258 | 0.020 |
Why?
|
| United States | 1 | 2021 | 7458 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2010 | 373 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 1972 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2010 | 414 | 0.020 |
Why?
|
| Peptides | 1 | 2011 | 547 | 0.020 |
Why?
|
| Adolescent | 1 | 2018 | 5888 | 0.020 |
Why?
|
| Female | 2 | 2018 | 30662 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 1137 | 0.020 |
Why?
|
| Aged | 1 | 2018 | 13259 | 0.010 |
Why?
|
| Middle Aged | 1 | 2018 | 16184 | 0.010 |
Why?
|
| Adult | 1 | 2018 | 15659 | 0.010 |
Why?
|